| Size | Price | Stock | Qty |
|---|---|---|---|
| 1mg |
|
||
| 5mg |
|
||
| 10mg |
|
||
| Other Sizes |
| Targets |
Fmoc-N(Me)-Sar10 does not have a defined biological target as it is a peptide building block and synthetic intermediate rather than a pharmacologically active compound. Its function is chemical—it serves as a building block for the synthesis of peptide ligand-drug conjugates. When incorporated into peptide conjugates, the sarcosine decamer provides a hydrophilic, flexible linker that can improve the pharmacokinetic properties of drug conjugates. The Fmoc protecting group enables solid-phase peptide synthesis. The compound itself is not evaluated for biological activity against specific targets.
|
|---|---|
| ln Vitro |
As a peptide building block, Fmoc-N(Me)-Sar10 exhibits no intrinsic pharmacological activity in vitro. Its utility is demonstrated in the synthesis of peptide ligand-drug conjugates. The compound supports cell adhesion, proliferation, and maintenance of cell phenotype when incorporated into peptide-based materials. In cell-based assays, the compound itself is not tested for biological activity. Instead, the peptide conjugates synthesized from this building block are evaluated for their pharmacological properties. The compound is used exclusively as a synthetic intermediate in peptide synthesis and bioconjugation research.
|
| ln Vivo |
Fmoc-N(Me)-Sar10 does not exhibit in vivo biological activity as it is not a therapeutic agent. The compound is used as a building block for the synthesis of peptide ligand-drug conjugates. Any in vivo effects would be associated with the final conjugates synthesized from this building block, not with the building block itself. The compound is not administered to animals in pharmacological studies and has no known physiological effects. Its role is strictly chemical—providing a sarcosine-based linker for peptide conjugate synthesis.
|
| Enzyme Assay |
In vitro assays for Fmoc-N(Me)-Sar10 focus on its use in solid-phase peptide synthesis rather than receptor binding. A standard protocol involves using the compound as a building block in automated peptide synthesizers. The Fmoc group is removed by piperidine treatment, and the free amine is coupled with the next amino acid using standard coupling reagents (HBTU, HATU, or DIC). The compound is soluble in DMSO (100 mg/mL) and is stored at -20°C. Quality control includes HPLC, mass spectrometry, and purity analysis.
|
| Cell Assay |
In vitro cell culture experiments with Fmoc-N(Me)-Sar10 derivatives typically involve testing the biological activity of peptide ligand-drug conjugates synthesized from this building block. Cells are cultured in appropriate media and treated with conjugates at concentrations ranging from 0.1-100 µM for 24-72 hours. Cell viability is assessed using MTT or CellTiter-Glo assays. The effects of conjugates on cell adhesion, proliferation, and phenotype are measured using appropriate assays. The building block itself is not evaluated in cellular systems; rather, the final conjugates are tested.
|
| Animal Protocol |
In vivo animal studies are not conducted with Fmoc-N(Me)-Sar10 itself, as it is a building block for peptide synthesis. When the compound is used to synthesize peptide ligand-drug conjugates, those final products undergo standard preclinical evaluation. Typical protocols for drug conjugates include pharmacokinetic studies in rodents (oral or intravenous administration, blood sampling for LC-MS/MS analysis), efficacy studies in tumor xenograft models, and toxicology studies (acute and repeated-dose toxicity, histopathology). These studies evaluate the safety and efficacy of the final conjugates, not the synthetic building block.
|
| ADME/Pharmacokinetics |
Pharmacokinetic properties of Fmoc-N(Me)-Sar10 are not characterized as it is not a drug substance. Based on its physicochemical properties (molecular weight 951.03, high polarity, peptide nature), the compound would be expected to have very low oral bioavailability due to poor membrane permeability. The Fmoc group would likely be cleaved in vivo, and the sarcosine decamer would be metabolized. However, the compound is not intended for human exposure and has not been evaluated in formal pharmacokinetic studies. For drug conjugates synthesized from this building block, pharmacokinetic properties are determined as part of drug development.
|
| Toxicity/Toxicokinetics |
Toxicological data for Fmoc-N(Me)-Sar10 are limited as it is a research reagent. Standard laboratory safety precautions should be followed when handling this compound, including the use of gloves, safety glasses, and working in a fume hood. The compound should be stored at -20°C. No acute toxicity data are available. The compound is not intended for drug, household, or other uses.
|
| References |
[1]. Chen Liuhong, et al. Multimeric bicyclic peptide ligands drug conjugates. Patent. WO2019162682.
|
| Additional Infomation |
Fmoc-N(Me)-Sar10 is a peptide building block used in solid-phase peptide synthesis for the preparation of peptide ligand-drug conjugates. It is a methylated sarcosine decamer that supports cell adhesion, proliferation, and maintenance of cell phenotype. The compound is also known as Fmoc-Sar10 and Fmoc-(Sar)10-OH. It has not undergone clinical trials and is not approved as a pharmaceutical. Its mechanism of action is chemical—serving as a building block for the synthesis of peptide conjugates.
|
| Molecular Formula |
C45H62N10O13
|
|---|---|
| Molecular Weight |
951.032990932465
|
| Exact Mass |
950.449
|
| CAS # |
2375600-56-7
|
| PubChem CID |
153425842
|
| Appearance |
White to off-white solid powder
|
| LogP |
-1.4
|
| Hydrogen Bond Donor Count |
1
|
| Hydrogen Bond Acceptor Count |
13
|
| Rotatable Bond Count |
23
|
| Heavy Atom Count |
68
|
| Complexity |
1860
|
| Defined Atom Stereocenter Count |
0
|
| SMILES |
CN(CC(=O)N(C)CC(=O)N(C)CC(=O)N(C)CC(=O)O)C(=O)CN(C)C(=O)CN(C)C(=O)CN(C)C(=O)CN(C)C(=O)CN(C)C(=O)CN(C)C(=O)OCC1C2=CC=CC=C2C3=CC=CC=C13
|
| InChi Key |
LWJFVEBBBTXGOQ-UHFFFAOYSA-N
|
| InChi Code |
InChI=1S/C45H62N10O13/c1-46(20-36(57)48(3)22-38(59)50(5)24-40(61)52(7)26-42(63)54(9)28-44(65)66)35(56)19-47(2)37(58)21-49(4)39(60)23-51(6)41(62)25-53(8)43(64)27-55(10)45(67)68-29-34-32-17-13-11-15-30(32)31-16-12-14-18-33(31)34/h11-18,34H,19-29H2,1-10H3,(H,65,66)
|
| Chemical Name |
2-[[2-[[2-[[2-[[2-[[2-[[2-[[2-[[2-[[2-[9H-fluoren-9-ylmethoxycarbonyl(methyl)amino]acetyl]-methylamino]acetyl]-methylamino]acetyl]-methylamino]acetyl]-methylamino]acetyl]-methylamino]acetyl]-methylamino]acetyl]-methylamino]acetyl]-methylamino]acetyl]-methylamino]acetic acid
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month Note: Please store this product in a sealed and protected environment (e.g. under nitrogen), avoid exposure to moisture and light. |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO: 100 mg/mL (105.15 mM)
|
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 1.0515 mL | 5.2575 mL | 10.5149 mL | |
| 5 mM | 0.2103 mL | 1.0515 mL | 2.1030 mL | |
| 10 mM | 0.1051 mL | 0.5257 mL | 1.0515 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
